RadNet stock (US75025X1000): Q1 2026 revenue surges 22% despite net loss

RadNet reported first-quarter 2026 results showing strong revenue growth and margin expansion, though the company continued to post net losses as it invests heavily in artificial intelligence and diagnostic imaging acquisitions. The company's Q1 performance reflects recovery in procedural volumes and expansion of its digital health platform, according to earnings call transcript as of May 12, 2026.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

RadNet: core business model

RadNet operates as a leading independent provider of outpatient diagnostic imaging services across the United States. The company runs a nationwide network of fixed-site imaging centers offering services including MRI, CT, mammography, ultrasound, and X-ray imaging. As of March 31, 2026, RadNet operated 435 imaging centers, according to SEC filing as of May 12, 2026. The company segments its business into two divisions: the Imaging Center segment, which generates revenue from diagnostic procedures, and the Digital Health segment, which includes AI-powered diagnostic tools and software platforms.

Q1 2026 financial performance and revenue drivers

RadNet achieved total service revenue of $575.6 million in the first quarter of 2026, compared with $471.4 million in the prior-year quarter, representing a 22.1% year-over-year increase. Adjusted EBITDA rose 36.3% in the same period. The revenue growth was primarily driven by higher commercial insurance revenue and expansion of the Digital Health platform, according to earnings call highlights as of May 12, 2026. The company reported a net loss attributable to common stockholders of $33.5 million, or $0.43 per share, compared with a loss of $37.9 million in the prior-year quarter.

Operating cash flow improved to $79.0 million in Q1 2026, while investing cash flows used $371.0 million, largely for acquisitions. The company spent approximately $264.1 million on the acquisition of Gleamer SAS, an artificial intelligence firm specializing in diagnostic imaging analysis. RadNet has also acquired iCAD, See-Mode, and CIMAR UK as part of its digital health expansion strategy.

Strategic focus on AI and digital health expansion

RadNet's aggressive acquisition strategy reflects a broader shift toward integrating artificial intelligence into diagnostic imaging workflows. The Gleamer acquisition represents a significant investment in AI-powered diagnostic tools that can enhance radiologist productivity and improve diagnostic accuracy. This positions RadNet as a consolidator in the diagnostic imaging space while building proprietary AI capabilities that could differentiate its service offerings from competitors.

Conclusion

RadNet's Q1 2026 results demonstrate strong operational momentum in its core imaging center business, with revenue growth accelerating to 22.1% year-over-year and adjusted EBITDA expanding at an even faster 36.3% rate. The company's continued net losses reflect significant capital deployment toward AI acquisitions and digital health platform development, a strategy aimed at positioning RadNet as a technology-enabled diagnostic imaging provider. For US investors, RadNet represents exposure to the consolidation and digitalization of outpatient diagnostic imaging, a sector benefiting from aging demographics and increased demand for preventive healthcare services.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.